Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Needham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy; Shares Will Rebound
August 10, 2015 7:08 AM EDTNeedham & Company upgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Strong Buy with a price target of $130.00.
Analyst Chan Messer commented, "ESPR shares have recently pulled back over regulatory concerns. Some investors feel that an evolution of thinking at the FDA about... More
UBS Reiterates Buy on Esperion Therapeutics (ESPR) Ahead of FDA Meeting; Sees Meaningful Upside
August 7, 2015 10:46 AM EDTUBS analyst Andrew Peters reiterated his Buy rating and $140 price target on Esperion Therapeutics (NASDAQ: ESPR), which suggests 152% upside from yesterday's close. Comments following in-line Q2 results and comments from the conference call which add color ahead of the FDA meeting.
"2Q15 financial results were in line with expectations, with management focusing the conf. call on addressing recent investor questions on ETC-1002 and regulatory risk," Peters commented. " With the recent pull-back in... More
Esperion Therapeutics (ESPR) Tops Q2 EPS by 3c
August 6, 2015 5:05 PM EDTEsperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.55), $0.03 better than the analyst estimate of ($0.58).
2015 Financial Outlook
Esperion expects that the net cash used to fund operating activities in 2015 will be approximately $42 million and that its cash and cash equivalents and investment securities available-for-sale will total... More
